The discovery: A walk in Valby

After plunging into the $MINEST (+3,06 %) into the stormy depths of the North Atlantic, we were in desperate need of solid ground under our feet again.

So what could be more natural than to take a look around right here in Denmark?

Yesterday, we took advantage of the beautiful spring weather to take a stroll through Valby in Copenhagen. And when you pass the massive brick buildings of the headquarters of H. Lundbeck A/S (ISIN: DK0061804770) $HLUN B (-2,01 %) you notice it:

Why look far afield for speculative returns when a global pharmaceutical specialist is printing money right on your doorstep?

This is exactly the opposite of the pure biotech gambling houses with no clear path to profitability that otherwise fall mercilessly through the cracks here. Lundbeck is a long-established Danish pharmaceutical substance.

Here is the formal disclaimer: II am not currently invested in H. Lundbeck. We are taking a purely analytical, neutral and ice-cold look at it today.

1. the business model: What does Lundbeck do?

Lundbeck does not make aspirin or plasters. They are a highly specialized global player in the field of diseases of the central nervous system (CNS). We are talking about drugs for depression, schizophrenia, Alzheimer's and migraine. Their blockbusters are called Rexulti, Trintellix and their latest growth engine Vyepti (an intravenous migraine treatment that is currently rolling out on the market).

2. market position & moat

The CNS field is the nemesis of the pharmaceutical industry. Brain research is incredibly complex and the failure rates in clinical trials are nowhere as high as here. This is their moat! Large pharmaceutical companies have often withdrawn from this field because it is too expensive and risky. Lundbeck has over 70 years of experience in this niche and dominates it profitably.

3. key figures (as of April 2026)

Current share price ~EUR 5.70

Market capitalization ~EUR 5.6 bn

Price/earnings ratio (P/E ratio)

~12.5 (extremely favorable!)

Price/cash flow ratio (KCV)

~8,5

Dividend yield

~3,6 %

4. core quality formula (the quality check)

Score = sales growth + operating margin

• Sales growth: ~ +7.5 % (driven by Vyepti and Rexulti).
• Operating margin (EBIT): A whopping 25.0 %.
• Result: 7.5 + 25.0 = 32.5

• Verdict: With 32.5 points, Lundbeck smashes our 25-point hurdle. This is first-class, qualitative growth and proves that the margins in the specialty pharma sector are gigantic.

5th Cashflow Quality Formula (The Cash Machine)

FCF = operating cash flow - CapEx

• Free cash flow: Lundbeck $HLUN B (-2,01 %) converts almost the entire profit into hard cash, as the factories are standing and CapEx is moderate (compared to heavy industry or network operators).
• FCF Yield: Is currently at a fantastic ~8,2 %.
• Verdict: Over 8 % means "very attractive". Lundbeck is an absolute cash machine and has zero problems with "balance sheet cosmetics".

6th Dividend Filter (Income-Core)

• Yield:
• 
  ~3,6 % (Check! Is above our 3.5% minimum requirement).
• Sustainability: The payout ratio is historically at a relaxed 30% to 40%. The cash flow covers the dividend twice and three times over. No pseudo-dividend on credit.

7. future prospects & strategy

The elephant in the room for pharma is always the "patent cliff effect" (loss of exclusivity). Trintellix will lose its patent protection at the end of the 2020s. That is why Lundbeck is now focusing massively on scaling up Vyepti and strategic acquisitions in the field of neuropeptides in order to fill the pipeline for 2030+.

8. competition & substitutability

There is competition from giants such as AbbVie or Biogen, but Lundbeck is more agile as a "pure play". At best, you can replace Lundbeck in your portfolio with a broad pharma ETF, but then you lose the concentrated CNS focus margin and the favorable valuation.

9. chart analysis (the current situation)

The share has had a tough time, because the market often drops pharmaceutical stocks like hot potatoes with impending patent expiries. The chart has been around EUR 4.70 has formed a massive concrete floor and is now moving back towards EUR 6.00 again. The downward trend has been broken.

10 Bargain Hunter's List (entry zones)

• Strong buy (bunker price): < EUR 5.10
• Fair entry: EUR 5.35 - 5.75 (current level)
• Expensive: > 7.40 EUR (This is where the market is then pricing in a flawless pipeline).

11. what does the CEO say? (The latest news)

CEO Charl van Zyl is firmly at the helm. His key message in recent calls: focus on profitability and "targeted business development deals". Instead of burning billions on risky giant takeovers, he buys clever small biotech assets to strengthen the company's own pipeline. He delivers exactly what value investors want to hear: Cash flow discipline.

12. analyst consensus: how do the pros see the stock?

The market hates uncertainty, and pharma is uncertainty. That is why the average analyst price target is "only" approx. EUR 6.45 (i.e. a moderate upside). Opinions differ: the value houses love the cash flow and the low P/E ratio of 12. The growth fanatics grumble about the patent expiries from 2028. A classic "hold / cautious buy" rating on the market.

My conclusion & future viability

Lundbeck $HLUN B (+1,48 %) is not a tenbagger, and that's not what we want here. If you look around Denmark, everyone is blindly pouncing on Novo Nordisk at a P/E of 40, but for the smart AOK investor, Lundbeck offers an absurd amount of safety at a P/E of 12.5, a margin of 25% and over 8% FCF yield. This is a massive quality compounder for the corner of the portfolio where the lights go out and the money works quietly and secretly.